Neuro-Therapeutics

NeuroTherapeutics is a biotechnology company focused on developing novel small molecule therapies for the treatment of neurological and psychiatric disorders. The company's primary research centers on the inhibition of kynurenine aminotransferase II (KAT II), an enzyme responsible for the production of kynurenic acid in the brain. By modulating kynurenic acid levels, NeuroTherapeutics aims to address cognitive impairment associated with schizophrenia (CIAS) and other neurodegenerative conditions like Alzheimer's and Parkinson's diseases. The company's lead programs are currently in the pre-clinical stage, leveraging foundational research into the kynurenine pathway to restore cognitive function.